NeuroPace Newsroom

Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20

Futu NewsSep 5 21:31

NeuroPace (NPCE) Gets a Buy From Lake Street

TipRanksSep 5 20:49

A Quick Look at Today's Ratings for NeuroPace(NPCE.US), With a Forecast Between $8 to $20

Futu NewsAug 15 21:02

Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target

BenzingaAug 14 21:47

NeuroPace Analyst Ratings

BenzingaAug 14 21:29

Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15

Futu NewsAug 14 19:34

Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20

Futu NewsAug 13 21:33

NeuroPace Analyst Ratings

BenzingaJul 16 00:58

Morgan Stanley Lowers Price Target on NeuroPace to $8 From $9.50, Keeps Equalweight Rating

MT NewswiresJul 15 19:13

Strong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPace

TipRanksMay 29 17:51

Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating

MT NewswiresMay 13 18:54

NeuroPace's Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating

TipRanksMay 10 13:30

Cantor Fitzgerald Corp.: The NeuroPace (NPCE.US) rating was confirmed and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $18.00.

Zhitong FinanceMay 9 23:10

NeuroPace Analyst Ratings

BenzingaMay 9 23:10

Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target

BenzingaMay 9 23:10

Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), NeuroPace (NPCE) and Dynavax (DVAX)

TipRanksMay 9 18:35

Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)

TipRanksMay 6 21:01

NeuroPace Analyst Ratings

BenzingaMar 14 21:20

Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16

MT NewswiresMar 14 20:30

NeuroPace Analyst Ratings

BenzingaMar 12 21:10